Current influenza virus vaccines rely upon the accurate prediction of circulating virus strains
months in advance of the actual influenza season in order to allow time for vaccine …

Highlights•Novel single cell technologies have enabled rapid generation of human
monoclonal antibodies.•These technologies have identified broadly neutralizing mAbs that …

Human monoclonal antibodies have been identified which neutralize broad spectra of
influenza A or B viruses. Here, we dissect the mechanisms by which such antibodies …

Despite available antivirals and vaccines, influenza continues to be a major cause of
mortality worldwide. Vaccination generally induces an effective, but strain-specific antibody …

The majority of influenza virus-specific antibodies elicited by vaccination or natural infection
are effective only against the eliciting or closely related viruses. Rare stem-specific …

Influenza viruses cause occasional pandemics and annual epidemics, thus persist as a
threat to human society. The high variability of viral envelope proteins resulting from …

High-performance neutralizing antibody against influenza virus typically recognizes the
globular head region of its hemagglutinin (HA) envelope glycoprotein. To-date, approved …

Highlights•Conserved epitopes on the influenza HA protein offer broad
protection.•Antibodies specific for these conserved epitopes are induced by exposure to …

Circulating influenza viruses evade neutralization in their human hosts by acquiring escape
mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines …

Highlights•Broadly neutralizing antibodies against influenza A and B represents a safe and
affordable alternative to convalescent plasma.•The large majority of broadly neutralizing …